Ivuxolimab - CAS 2128729-41-7

Ivuxolimab is a fully human immunoglobulin G2 (IgG2) monoclonal antibody functioning as an agonist that targets the OX40 receptor (CD134), which selectively binds to the OX40 receptor expressed on the surface of activated CD4+ and CD8+ T cells without inducing antibody-dependent cellular cytotoxicity. Ivuxolimab can promote T cell proliferation, enhance cell survival, stimulate cytokine secretion (such as IFN-γ and IL-2), inhibit the suppressive function of regulatory T cells (Tregs), and potentiate anti-tumor immune responses, enabling its use in the study of cancers including melanoma, hepatocellular carcinoma, and head and neck squamous cell carcinoma.

Interleukin, TNF

Apoptosis, Immunology/Inflammation

2128681

0.967

-20°C

Ice Packs

Inhibitory Antibodies